Novo Nordisk defended its next-generation obesity drug candidate CagriSema on Wednesday following late-stage trial data ...
The world’s biggest drugmaker Eli Lilly has forecast that profits for the year will beat expectations, after two choppy quarters when disappointing sales of its blockbuster weight-loss drugs led to ...
New poll shows about half of U.S. adults believe it is a good thing for adults to use weight-loss drugs if they are ...
Novo Nordisk is under pressure from investors for more information about its next-generation obesity drug candidate CagriSema ...
Eli Lilly's Ozempic-rivaling weight-loss pill orforglipron could be available in early 2026. Its retatrutide may be as ...
Novo Nordisk shares rose sharply after the Danish pharmaceutical giant said an experimental weight-loss shot helped patients ...
Novo Nordisk said on Wednesday it plan to file its experimental next-generation obesity drug CagriSema for regulatory ...
News Medical on MSN3d
Prescription trends for obesity medications surge, tied to growing interest in GLP-1 drugsObesity medication prescriptions reached 1.5 million, driven by GLP-1 agents semaglutide and tirzepatide, as public interest ...
Cost is a major obstacle for many. The drugs can be expensive without insurance, with out-of-pocket expenses reaching ...
Alexandra Sowa's new book The Ozempic Revolution is intended to be the "first comprehensive user guide" to GLP-1 drugs like ...
CagriSema, which underperformed expectations in its first Phase 3 test, will be studied at different doses and for longer ...
Eli Lilly expects to read out results from a study in people with obesity and osteoarthritis of the knee in 2025.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback